» Articles » PMID: 39866300

Therapeutic Efficacy of Medicinal Plants with Allopathic Medicine in Musculoskeletal Diseases

Overview
Publisher Fortune Journals
Date 2025 Jan 27
PMID 39866300
Authors
Affiliations
Soon will be listed here.
Abstract

Musculoskeletal diseases encompass a diverse array of disorders affecting the muscles, bones, joints, and connective tissues, leading to significant impairments in mobility, function, and quality of life. Affecting over 1.3 billion individuals globally, musculoskeletal diseases represent a major source of disability and economic burden. Conventional treatment modalities, including pharmacological interventions and surgical procedures, are frequently limited by adverse side effects, prolonged recovery periods, and patient dissatisfaction, particularly when focused solely on symptom management. In response, complementary and alternative medicine, particularly the use of medicinal plants, has garnered increasing interest to enhance the management of musculoskeletal diseases. Medicinal plants possess a wide spectrum of pharmacologically active compounds with anti-inflammatory, analgesic, and antioxidant properties, making them promising adjuncts to conventional therapies. This review critically evaluates the potential synergy between medicinal plants and allopathic medicine for the management of musculoskeletal diseases, with an emphasis on integrated therapy that combines both modalities. Specifically, a critical discussion is presented on how medicinal plants with scientifically supported pharmacological properties can augment the therapeutic efficacy of conventional medications, reduce their doses, and mitigate adverse effects. Furthermore, the challenges associated with incorporating herbal medicine into established healthcare systems are discussed, including the need for rigorous clinical validation, standardization, and regulatory frameworks. Overall, the article underscores the potential of integrated therapeutic approaches to improve clinical outcomes, enhance patient well-being, and establish a more sustainable model for the treatment of musculoskeletal diseases.

References
1.
Connizzo B, Yannascoli S, Tucker J, Caro A, Riggin C, Mauck R . The detrimental effects of systemic Ibuprofen delivery on tendon healing are time-dependent. Clin Orthop Relat Res. 2013; 472(8):2433-9. PMC: 4079885. DOI: 10.1007/s11999-013-3258-2. View

2.
Wilsdon T, Whittle S, Thynne T, Mangoni A . Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019; 1:CD012722. PMC: 6353064. DOI: 10.1002/14651858.CD012722.pub2. View

3.
Varoga D, Drescher W, Pufe M, Groth G, Pufe T . Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin Orthop Relat Res. 2009; 467(12):3273-82. PMC: 2772917. DOI: 10.1007/s11999-009-1076-3. View

4.
Sonaglia A, Comoretto R, Pasut E, Treppo E, Del Frate G, Colatutto D . Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak. Viruses. 2022; 14(7). PMC: 9316145. DOI: 10.3390/v14071462. View

5.
Su S, Dehnade F, Zafarullah M . Regulation of tissue inhibitor of metalloproteinases-3 gene expression by transforming growth factor-beta and dexamethasone in bovine and human articular chondrocytes. DNA Cell Biol. 1996; 15(12):1039-48. DOI: 10.1089/dna.1996.15.1039. View